

Supplementary Data

Plasma Amyloid- β Levels and Prognosis in Incident Dementia Cases of the 3-City Study

Audrey Gabelle^{a,b,c,*}, Florence Richard^{d,e,f}, Laure-Anne Gutierrez^g, Susanna Schraen^{f,h}, Fleur Delvaⁱ, Olivier Rouaud^j, Luc Buée^{f,h}, Jean-François Dartiguesⁱ, Jacques Touchon^{a,c,g}, Jean-Charles Lambert^{d,e} and Claudine Berr^{a,c,g}

^a*Department of Neurology, Centre Mémoire Ressources Recherche Languedoc-Roussillon, CHRU Gui de Chauliac Hospital, Montpellier, France*

^b*INSERM-UMI U1040, IRB, Saint Eloi Hospital, Montpellier, France*

^c*University Montpellier 1, Montpellier, France*

^d*INSERM U744, Lille, France, and Institut Pasteur de Lille, France*

^e*Université de Lille Nord de France, Lille, France*

^f*CHRU de Lille, Lille, France*

^g*INSERM U1061, La Colombière Hospital, Montpellier, France*

^h*INSERM U837, Lille, France*

ⁱ*INSERM U897, Victor Segalen University, Bordeaux, France*

^j*Department of Neurology, CMRR de Dijon, CHRU Dijon, Dijon, France*

*Correspondence to: Dr. Audrey Gabelle, MD, PhD, CMRR Montpellier, CHRU Gui de Chauliac, Department of Neurology, F-34295 Montpellier Cedex 5, France. Tel.: +33 46733 7947; Fax: +33 46733 6036; E-mail: a-gabelle@chu-montpellier.fr.

Supplementary Table 1

Plasma A β levels and mortality in the 120 incident dementia cases and in the 81 AD cases risk associated with each 5 pg/ml increase: crude and adjusted hazard ratios (HRs) and the 95% confidence interval (CI). The adjusting factors were gender, age, educational level, center, alcohol consumption, hypertension, IADL, depression, cognitive score at baseline and a history of vascular disease

	All dementias						AD cases								
	Alive (n = 57)			Deceased (n = 63)			Alive (n = 46)			Deceased (n = 35)					
	m (SD)	Crude HR [95% CI]	p	Adjusted HR [95% CI]	p	m (SD)	Crude HR [95% CI]	p	Adjusted HR [95% CI]	p	m (SD)	Crude HR [95% CI]	p	Adjusted HR [95% CI]	p
A β ₄₀	244.2 (49.9)	1.00 [0.98;1.03]	0.78	1.00 [0.98;1.02]	0.78	241.1 (45.7)	1.01 [0.98;1.04]	0.50	1.01 [0.97;1.04]	0.73	253.7 (57.3)	1.01 [0.98;1.04]	0.50	1.01 [0.97;1.04]	0.73
A β ₄₂	39.1 (9.6)	0.97 [0.85;1.10]	0.57	0.91 [0.80;1.04]	0.15	38.7 (9.8)	1.01 [0.86;1.20]	0.89	0.94 [0.77;1.14]	0.51	41.2 (11.0)	1.01 [0.86;1.20]	0.89	0.94 [0.77;1.14]	0.51
A β ₄₀	256.6 (57.1)	1.01 [0.99;1.30]	0.42	1.01 [0.99;1.02]	0.63	254.2 (58.8)	1.01 [0.98;1.04]	0.58	1.00 [0.98;1.03]	0.78	279.6 (64.0)	1.01 [0.98;1.04]	0.58	1.00 [0.98;1.03]	0.78
A β _{n-42}	26.4 (7.1)	1.00 [0.97;1.03]	0.99	0.95 [0.80;1.11]	0.50	26.6 (7.6)	1.02 [0.82;1.26]	0.88	0.90 [0.71;1.14]	0.36	28.3 (8.7)	1.02 [0.82;1.26]	0.88	0.90 [0.71;1.14]	0.36
ratio A β ₄₂ /A β ₄₀	0.164 (0.046)	0.82 [0.47;1.49]	0.51	0.69 [0.35;1.37]	0.29	0.164 (0.048)	0.69 [0.28;1.73]	0.43	0.48 [0.17;1.37]	0.17	0.164 (0.033)	0.69 [0.28;1.73]	0.43	0.48 [0.17;1.37]	0.17
ratio A β _{n-42} /A β _{n-40}	0.106 (0.030)	0.72 [0.33;1.57]	0.41	0.58 [0.24;1.38]	0.22	0.107 (0.032)	0.72 [0.24;2.22]	0.57	0.37 [0.09;1.47]	0.16	0.104 (0.028)	0.72 [0.24;2.22]	0.57	0.37 [0.09;1.47]	0.16